Mind+ Neurology is advancing medical research and offering hope to patients living with migraine. Mind+ is an authorized site for a new Episodic Migraine clinical trial. They made history recently by randomizing the first patient in the world! Aaron Hart, Co-Founder & CEO, shares that people who experience 3 or more migraines per month are eligible to participate in this clinical trial. There is no charge for the appointments and compensation of up to $1,200 is being offered.
Kelly Reynolds, Director of Clinical Strategy, explores the class of migraine medications known as CGRP (calcitonin gene-related peptide) inhibitors, which have been on the market since 2018. According to Reynolds, these medications are not only more effective at treating head pain but also tend to have fewer side effects. What’s more, the American Headache Society has issued updated recommendation guidelines to offer CGRP medications as the first-line treatment for the prevention of headache and migraine.
To find out more about the new clinical trial, visit mindpl.us/az. To learn more about headache treatment call 888-585-7975 or visit: www.mindplusclinic.com